An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link

Two factors contribute to Burkitt lymphoma (BL) pathogenesis, a chromosomal translocation leading to c-myc oncogene deregulation and infection with Epstein-Barr virus (EBV). Although the virus has B cell growth–transforming ability, this may not relate to its role in BL since many of the transforming proteins are not expressed in the tumor. Mounting evidence supports an alternative role, whereby EBV counteracts the high apoptotic sensitivity inherent to the c-myc–driven growth program. In that regard, a subset of BLs carry virus mutants in a novel form of latent infection that provides unusually strong resistance to apoptosis. Uniquely, these virus mutants use Wp (a viral promoter normally activated early in B cell transformation) and express a broader-than-usual range of latent antigens. Here, using an inducible system to express the candidate antigens, we show that this marked apoptosis resistance is mediated not by one of the extended range of EBNAs seen in Wp-restricted latency but by Wp-driven expression of the viral bcl2 homologue, BHRF1, a protein usually associated with the virus lytic cycle. Interestingly, this Wp/BHRF1 connection is not confined to Wp-restricted BLs but appears integral to normal B cell transformation by EBV. We find that the BHRF1 gene expression recently reported in newly infected B cells is temporally linked to Wp activation and the presence of W/BHRF1-spliced transcripts. Furthermore, just as Wp activity is never completely eclipsed in in vitro–transformed lines, low-level BHRF1 transcripts remain detectable in these cells long-term. Most importantly, recognition by BHRF1-specific T cells confirms that such lines continue to express the protein independently of any lytic cycle entry. This work therefore provides the first evidence that BHRF1, the EBV bcl2 homologue, is constitutively expressed as a latent protein in growth-transformed cells in vitro and, in the context of Wp-restricted BL, may contribute to virus-associated lymphomagenesis in vivo.

[1]  J. Sample,et al.  Epstein-Barr Virus Small RNAs Potentiate Tumorigenicity of Burkitt Lymphoma Cells Independently of an Effect on Apoptosis , 2000, Journal of Virology.

[2]  J. Strominger,et al.  Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Rickinson,et al.  CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines , 2005, Journal of Virology.

[4]  M. Rowe,et al.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[6]  P. L. Deininger,et al.  DNA sequence and expression of the B95-8 Epstein—Barr virus genome , 1984, Nature.

[7]  K. Takada,et al.  Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV , 1994, Journal of virology.

[8]  E. Kieff,et al.  Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Young,et al.  Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.

[10]  K. Takada,et al.  Synchronous and sequential activation of latently infected Epstein-Barr virus genomes , 1989, Journal of virology.

[11]  J. Sample,et al.  Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein , 1996, Journal of virology.

[12]  D. Kerr,et al.  Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells , 2002, Cell Death and Differentiation.

[13]  M. Bonneville,et al.  Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. , 2004, Blood.

[14]  M. Perricaudet,et al.  Epstein-Barr virus mRNAs produced by alternative splicing. , 1986, Nucleic acids research.

[15]  W. Hammerschmidt,et al.  Epstein-Barr Virus Nuclear Antigen 2 (EBNA2) Gene Deletion Is Consistently Linked with EBNA3A, -3B, and -3C Expression in Burkitt's Lymphoma Cells and with Increased Resistance to Apoptosis , 2005, Journal of Virology.

[16]  Anton J. Enright,et al.  Identification of Virus-Encoded MicroRNAs , 2004, Science.

[17]  A. Rickinson,et al.  Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells , 2006, Proceedings of the National Academy of Sciences.

[18]  E. White,et al.  Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. , 2002, Genes & development.

[19]  S. Tangye,et al.  Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients. , 2008, Blood.

[20]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  E. Hui,et al.  Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. , 2006, The Journal of general virology.

[22]  D. Kwong,et al.  An Epstein-Barr virus–encoded microRNA targets PUMA to promote host cell survival , 2008, The Journal of experimental medicine.

[23]  H. Bujard,et al.  Stringent doxycycline-dependent control of gene activities using an episomal one-vector system , 2005, Nucleic Acids Research.

[24]  Chen-feng Qi,et al.  Burkitt Lymphoma in the Mouse , 2000, The Journal of experimental medicine.

[25]  B. Kempkes,et al.  c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Strominger,et al.  Isolation and characterization of cDNA clones corresponding to transcripts from the BamHI H and F regions of the Epstein-Barr virus genome , 1987, Journal of virology.

[27]  L. Xing,et al.  Epstein-Barr Virus BHRF1 Micro- and Stable RNAs during Latency III and after Induction of Replication , 2007, Journal of Virology.

[28]  K. Takada,et al.  Epstein-Barr Virus Contributes to the Malignant Phenotype and to Apoptosis Resistance in Burkitt’s Lymphoma Cell Line Akata , 1998, Journal of Virology.

[29]  A. Nanbo,et al.  Replacement of the Epstein-Barr Virus Plasmid with the EBER Plasmid in Burkitt's Lymphoma Cells , 2001, Journal of Virology.

[30]  A. Rickinson,et al.  Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. , 2007, Hematology. American Society of Hematology. Education Program.

[31]  P. Farrell,et al.  Epstein–Barr virus and Burkitt lymphoma , 2007, Journal of Clinical Pathology.

[32]  S. Lowe,et al.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.

[33]  Robert E. White,et al.  Two Epstein–Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma , 2008, Oncogene.

[34]  I. Magrath The pathogenesis of Burkitt's lymphoma. , 1990, Advances in cancer research.

[35]  E. Kieff,et al.  Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. , 1987, Virology.

[36]  M. Rowe,et al.  Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. , 1994, The Journal of general virology.

[37]  Y. Kawaguchi,et al.  Truncated Form of the Epstein-Barr Virus Protein EBNA-LP Protects against Caspase-Dependent Apoptosis by Inhibiting Protein Phosphatase 2A , 2007, Journal of Virology.

[38]  A. Rickinson,et al.  Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2 , 2002, Nature Medicine.

[39]  T. Frey,et al.  Nucleic acid dyes for detection of apoptosis in live cells. , 1995, Cytometry.

[40]  B. Sugden,et al.  Epstein-Barr virus provides a survival factor to Burkitt's lymphomas , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[42]  S. Maruo,et al.  Oncogenic Role of Epstein-Barr Virus-Encoded RNAs in Burkitt’s Lymphoma Cell Line Akata , 1999, Journal of Virology.

[43]  A. Rickinson,et al.  Methylation Status of theEpstein-Barr Virus (EBV) BamHI W Latent Cycle Promoter and Promoter Activity: Analysis with Novel EBV-Positive Burkitt and LymphoblastoidCell Lines , 2006, Journal of Virology.

[44]  W. Hammerschmidt,et al.  The Epstein–Barr virus lytic program is controlled by the co‐operative functions of two transactivators , 2000, The EMBO journal.

[45]  J. Strominger,et al.  Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Alexandra Schäfer,et al.  Epstein–Barr Virus MicroRNAs Are Evolutionarily Conserved and Differentially Expressed , 2006, PLoS pathogens.

[47]  J. Pevsner,et al.  Viral Bcl-2 homologs and their role in virus replication and associated diseases. , 2004, Biochimica et biophysica acta.

[48]  J. Strominger,et al.  Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[49]  L. T. Krug,et al.  Variable Methylation of the Epstein-Barr Virus Wp EBNA Gene Promoter in B-Lymphoblastoid Cell Lines , 2004, Journal of Virology.

[50]  A. Rickinson,et al.  Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones , 1991, Journal of virology.

[51]  W. Hammerschmidt,et al.  Epstein-Barr Virus Provides a New Paradigm: A Requirement for the Immediate Inhibition of Apoptosis , 2005, PLoS biology.

[52]  G. Williams,et al.  The Epstein-Barr virus gene BHRF1, a homologue of the cellular oncogene Bcl-2, inhibits apoptosis induced by gamma radiation and chemotherapeutic drugs. , 1996, Advances in experimental medicine and biology.

[53]  S. Kawanishi,et al.  Epstein-Barr virus BHRF1 functions downstream of Bid cleavage and upstream of mitochondrial dysfunction to inhibit TRAIL-induced apoptosis in BJAB cells. , 2002, Biochemical and biophysical research communications.

[54]  Chen-feng Qi,et al.  Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. , 2005, Blood.

[55]  P. Rivailler,et al.  Complete Genomic Sequence of an Epstein-Barr Virus-Related Herpesvirus Naturally Infecting a New World Primate: a Defining Point in the Evolution of Oncogenic Lymphocryptoviruses , 2002, Journal of Virology.

[56]  D. Markovitz,et al.  Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. , 1995, The Journal of infectious diseases.

[57]  L. Resnick,et al.  The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression , 1994, Journal of virology.